MedTrace Logo

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

NCT04155918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-19

No results posted yet for this study

Summary

The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.

Conditions

  • Gout Patients

Interventions

DRUG

Group 1: AR882 Alone and in Combination with Febuxostat (FBX)

AR882 + Febuxostat, AR882 alone, Febuxostat alone

DRUG

Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

AR882 + Allopurinol, AR882 alone, Allopurinol alone

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • Christopher Wynne, MBChB, Grad Dip Pharm Med · Christchurch Clinical Studies Trust Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2020-09-03
Completion
2020-09-03
FDA Drug
Yes

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155918 on ClinicalTrials.gov